Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Three Or More Carbocyclic Rings Patents (Class 514/33)
  • Publication number: 20080171787
    Abstract: Colchicine neoglycosides, method for their synthesis and methods for their use are disclosed. The invention provides analogs of colchicine glycosylated to include a sugar moiety on a colchicine scaffold that is generally unglycosylated in nature. The colchicine neoglycosides disclosed herein are shown to have cytotoxic effects equivalent to at least the known cytotoxins paclitaxel and doxorubicin. Further, the neoglycosides disclosed according to the invention have physiologic effects not previously recognized in the alkaloid family that includes colchicine but recognized in other cytotoxic drug families such as the taxanes which act by stabilizing tubulin formation.
    Type: Application
    Filed: October 8, 2007
    Publication date: July 17, 2008
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Jon S. Thorson, Ahmed Aqeel
  • Patent number: 7387790
    Abstract: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: June 17, 2008
    Assignee: Cornerstone Pharmaceuticals
    Inventors: Robert Shorr, Robert Rodriguez
  • Publication number: 20080124303
    Abstract: A novel method of treating and preventing viral diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of viral infections and the diseases associated with such viral infections. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made compositions comprising a substance exhibiting Tubercin and/or SSM activity or a functional derivative thereof.
    Type: Application
    Filed: July 12, 2007
    Publication date: May 29, 2008
    Inventor: Colm King
  • Publication number: 20080119420
    Abstract: Two hitherto unreported novel triterpene saponins were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of the triterpene saponin fraction have been elucidated to possess anti-inflammatory and analgesic activity. These two novel triterpene saponins and the triterpene saponin fraction may be used as pharmaceutical compositions in humans and mammals in need of such treatment.
    Type: Application
    Filed: November 17, 2006
    Publication date: May 22, 2008
    Inventors: Liang LIU, Jing Rong Wang, Hua Zhou, Zhi Hong Jiang
  • Patent number: 7371889
    Abstract: The invention relates to new chemical compounds that inhibit the various enzymes in the arachidonic acid pathway implicated in inflammatory disease conditions.
    Type: Grant
    Filed: March 11, 2007
    Date of Patent: May 13, 2008
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagebhuananam, Rajendran Ramanujam, Subbalakshmi Prakash
  • Patent number: 7323452
    Abstract: A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives include multivalent transition metal ions, as well as complexes thereof, and NAD+ which enhance the oxidation reaction. The method described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: January 29, 2008
    Assignee: Wardan, L.L.C.
    Inventors: Ward B. Bowen, Jr., Daniel S. Daniel
  • Patent number: 7288534
    Abstract: Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: October 30, 2007
    Assignee: Center for Molecular Medicine and Immunology
    Inventors: David Modrak, David M. Goldenberg
  • Publication number: 20070249543
    Abstract: A phyto-pharmacological substance, namely a saponin, precursor or derivative, with emulsifying/detergent/surfactant/fat dissolving properties administered into the systemic circulation of a subject via a variety of routes of administration including the topical-dermatological such as a skin patch, the oral-digestive in association with solubility or permeability or stability enhancers, alone or in synergitic combination, the topical-mucous membrane administration such as the sublingual route, the intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory in form of inhaled microcrystals, the intrarterial, the saponin substance reaching and dissolving with its emulsifying properties the cholesterol aggregates and in general the lipidic core within the atherosclerotic plaque.
    Type: Application
    Filed: October 4, 2006
    Publication date: October 25, 2007
    Inventors: Filiberto Zadini, Giorgio Zadini
  • Publication number: 20070243238
    Abstract: A method for treating a mouth sore opposite a tooth by adhering an oral patch on the tooth to speed healing and relieve pain. The oral patch is placed either directly on the portion of the tooth that comes into contact with the sore or is first place onto the sore and then adhered to the tooth. The patch may be a blob of hydrophilic gums. If certain medications are applied to a mouth sore using an oral patch that delivers the medication for at least 30 minutes and the patches are used for at least two or more hours per day, the method reduces the healing time for mouth sores from typical 10-14 days to 1-5 days. The method can be used with various antimicrobials, glucocorticoids or anthihistamines incorporated into the patch that reduce inflammation or speed the healing of mouth sores.
    Type: Application
    Filed: December 15, 2006
    Publication date: October 18, 2007
    Inventor: Jeffrey T. Haley
  • Patent number: 7262285
    Abstract: Novel compounds such as compounds designated herein as Xanifolia-Y or -Y3, -Y1, -Y2, -Y8, -Y9 and -Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapindaceae family, such as Xanthoceras sorbifolia, or other natural sources or products.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: August 28, 2007
    Assignee: Pacific Arrow Limited
    Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
  • Patent number: 7232805
    Abstract: The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5?-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: June 19, 2007
    Assignee: Inflabloc Pharmaceuticals, Inc.
    Inventors: Ned M. Weinshenker, Frederick G. West, Barbara A. Araneo, Weiping Li
  • Patent number: 7220428
    Abstract: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: May 22, 2007
    Assignee: Cornerstone Pharmaceuticals
    Inventors: Robert Shorr, Robert Rodriguez
  • Patent number: 7204996
    Abstract: This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of (a) evaluating the subject to determine if the subject has relapsed or refractory cancer; (b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.
    Type: Grant
    Filed: June 10, 2005
    Date of Patent: April 17, 2007
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael Andreeff, Elihu H Estey
  • Patent number: 7202222
    Abstract: Methods for treating obesity, reducing total weight and reducing body fat mass by administering a composition comprising dihydroquercetins and root-derived aralosides A, B, C and D is disclosed.
    Type: Grant
    Filed: September 11, 2003
    Date of Patent: April 10, 2007
    Assignee: National Bioscience Corporation
    Inventors: Arthur Ramazanov, Zakir Ramazanov
  • Patent number: 7163702
    Abstract: This present invention discloses use of a chloroform/solvent mixture extraction at different solvent-to-feed ratios, followed by evaporation and extraction with ethyl acetate/water; followed by chromatography of the water phase in Teflon or other non-polar resin and Silica gel column chromatography for recovering of individual triterpene glycosides (saponins) of high purity from the freeze dried or spray dried cooking water or dried powderized tissues of the industrial processed sea cucumber Cucumaria frondosa. A resulting glycoside Frondoside A stimulates lysosomal activity of peritoneal macrophages, phagocytosis and oxidative burst in the macrophages at concentrations significantly less than for acute toxicity, hemolysis and sea urchin embryo toxicity.
    Type: Grant
    Filed: June 6, 2005
    Date of Patent: January 16, 2007
    Inventors: Sergey Anatolievuch Avilov, Vladimir Ivanovich Kalinin, Alexandra Sergeevna Silchenko, Dmitry Lvovich Aminin, Irina Grigorevna Agafonova, Valentin Aronovich Stonik, Peter D. Collin, Carl Woodward
  • Patent number: 7157078
    Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: January 2, 2007
    Assignee: The University of Florida Research Foundation, Inc.
    Inventors: Philip Frederick Brode, III, Garry Steven Garren, Leo Timothy Laughlin, Randall Stryker Matthews, Dale Edwin Barker, Daniel James Kinne, Gary Eugene McKibben, Christopher Miles Miller, Timothy Robert Probst
  • Patent number: 7153877
    Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: December 26, 2006
    Assignee: Interhealth Nutraceuticals Incorporated
    Inventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
  • Patent number: 7144867
    Abstract: The present invention relates to new classes of anti-cancer compounds. In particular, the present invention provides glycoside compounds as anti-cancer agent, alone, or in combination with other anti-cancer agents or therapies.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: December 5, 2006
    Assignees: Northwestern University, Coastside Bio Resources
    Inventors: Thomas E. Adrian, Peter D. Collin
  • Patent number: 7132403
    Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: November 7, 2006
    Assignees: Board of Trustees of Michigan State University, Regents of the University of California
    Inventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow
  • Patent number: 7119110
    Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: October 10, 2006
    Assignee: Interhealth Nutraceuticals Incorporated
    Inventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
  • Patent number: 7105492
    Abstract: Camptothecin derivatives of camptothecin of formula (I) exhibit antitumor activity and show a good therapeutic index and are used in the treatment of tumors, viral infections and antiplasmodium falciparum.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: September 12, 2006
    Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Istituo Nazionale Per Lo Studio E La Cura Dei Tumori
    Inventors: Sabrina Dallavalle, Sergio Penco, Claudio Pisano, Franco Zunino
  • Patent number: 7094431
    Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: August 22, 2006
    Inventor: Mickey L. Peshoff
  • Patent number: 7091189
    Abstract: By using a combination of amrubicin or a pharmaceutically acceptable salt thereof with another medicament for treating lung cancer (irinotecan, vinorelbine, gemcitabine, etc.), it is intended to provide medicaments for treating lung cancer having an improved antitumor therapeutic effect on lung cancer and reduced side effects. Lung cancer can be effectively treated using these medicaments.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: August 15, 2006
    Inventors: Toshihiro Noguchi, Akemi Baba
  • Patent number: 7071233
    Abstract: An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochemicals, benzalkonium chloride, a sterile water solution, and folic acid.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: July 4, 2006
    Inventor: Meryl Squires
  • Patent number: 7060686
    Abstract: Methods for treating, preventing, or inhibiting diseases and disorders associated with inflammation, cell-proliferation, and pain comprising the administration of a compound having the structural formula wherein R1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R2, R3, and R4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R5 is hydrogen, CH3, or CH2OH, and R6 is an organo group such as a hydrocarbon having from 1 to 10 carbon atoms are disclosed. Other seco-pseudopterosins and compounds related to pseudopterosins are disclosed.
    Type: Grant
    Filed: August 2, 2004
    Date of Patent: June 13, 2006
    Assignees: The Regents of the University of California, Florida Atlantic University Board of Trustees
    Inventors: Robert S. Jacobs, Russell G. Kerr
  • Patent number: 7049301
    Abstract: This invention relates to quercetin derivative, its preparation, and a pharmaceutical combination, as well as their medical uses for the prevention or treatment of diseases related to 5HT1A receptor or neuron cell damages, including Alzeheimer's disease, drug or alcohol dependence, sleep disorders or panic state; and for delaying senility, improving learning and memory, preventing and treatment of neuron cell damages caused by various kinds of cerebral damages.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: May 23, 2006
    Assignee: Academy of Military Medical Sciences Institute of Pharmacology and Toxicology
    Inventors: Yimin Zhao, Ming Yang, Yunfeng Li, Xinhui Luan, Zhipu Luo
  • Patent number: 7008929
    Abstract: The present invention relates to the use of a sapogenin, chosen from diosgenin and hecogenin, and/or of a plant extract containing at least one of these sapogenins. A preferred use is the treatment of oligoseborrheic dry skin. Another preferred use is the treatment of dry scalp. Compositions containing these sapogenins are also described.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: March 7, 2006
    Assignee: L'Oreal
    Inventors: Gilles Rubinstenn, Bruno Buan
  • Patent number: 7008648
    Abstract: A method of suppressing or curbing appetite and treating or preventing obesity comprising administering to a human or other mammal in need of such treatment an effective amount of plant material derived or derivable from plants of the genera Stapelia and Orbea.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: March 7, 2006
    Assignee: Novartis Nutrition AG
    Inventors: David Gregory Corley, James Miller
  • Patent number: 6946490
    Abstract: An improved medical treatment and medicine is provided to quickly and safely resolve herpes and other microbial infections. The inexpensive user-friendly medicine can be applied and maintained on the infected region until the physical symptoms of the disease disappears and the patient is comfortable and has a normal appearance. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent. In the preferred form, the medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: September 20, 2005
    Inventor: Meryl Squires
  • Patent number: 6929802
    Abstract: This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of (a) evaluating the subject to determine if the subject has relapsed or refractory cancer; (b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.
    Type: Grant
    Filed: April 18, 2003
    Date of Patent: August 16, 2005
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael Andreeff, Elihu H. Estey
  • Patent number: 6903076
    Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: June 7, 2005
    Assignees: Board of Trustees of Michigan State University, The Regents of the University of California
    Inventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow
  • Patent number: 6900239
    Abstract: A method for enhancing the efficacy of chemotherapy in the treatment of cancer in animals, particularly humans, is provided wherein isocoumarin derivatives that exhibit unique chemopotentiation properties are employed in a combination treatment with chemotherapy.
    Type: Grant
    Filed: February 23, 2002
    Date of Patent: May 31, 2005
    Assignee: ILWZ ILEX Products, Inc.
    Inventors: Naoki Agata, Surender Kharbanda
  • Patent number: 6894030
    Abstract: The synergistic combination of a loop diuretic and a cardiac glycoside is useful in the treatment of DNA viral infections.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: May 17, 2005
    Assignee: Henderson Morley Research and Development Limited
    Inventor: Christopher Edward Hartley
  • Patent number: 6875746
    Abstract: Anthraquinones are described which have anticancer or antitumor activity and which are useful for inhibiting cancer cells and cells comprising tumors in vitro or in vivo. Preferably, the anthraquinones have the chemical formula: wherein R1 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; R2 is a group containing 1-12 carbons selected from the group consisting of alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate and combinations thereof; and R3 is a group containing 1 to 12 carbons selected from the group consisting of methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, and combinations thereof.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: April 5, 2005
    Assignee: Board of Trustees of Michigan State University
    Inventors: Muraleedharan G. Nair, Robert H. Cichewicz, Navindra P. Seeram, Yanjun Zhang
  • Patent number: 6875745
    Abstract: We have discovered that the administration of a G1 and/or S phase drug such as ?-lapachone in combination with a G2/M drug such as a taxane derivative such as paclitaxel resulted in a greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a ?-lapachone, or a derivative or analog thereof.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: April 5, 2005
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventors: Arthur B. Pardee, Chiang J. Li, Youzhi Li
  • Patent number: 6872709
    Abstract: The present invention provides a therapeutic agent and therapeutic method for treatment of mastitis in livestock comprising glycyrrhizin and pharmaceutically acceptable salts thereof as effective ingredients.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: March 29, 2005
    Assignee: Kyoritsu Seiyaku Corporation
    Inventors: Katsuo Kumagai, Kenzo Kai, Ken-ichi Komine
  • Patent number: 6852694
    Abstract: The present invention is directed to stabilized insulin composition comprising a mixture of insulin species such as insulin and an insulin analog. As disclosed herein, insulin compositions comprising a mixture of insulin and insulin analog species form heterodimeric complexes having a greater stability than the homodimeric complexes formed in compositions comprising single insulin species. Consequently, the present invention provides methods for stabilizing insulin molecules, methods for identifying stable heterodimeric insulin complexes and stabilized insulin compositions.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: February 8, 2005
    Assignee: Medtronic MiniMed, Inc.
    Inventors: William Peter Van Antwerp, Poonam S. Gulati
  • Patent number: 6838443
    Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: January 4, 2005
    Assignees: Board of Trustees of Michigan State University, The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow
  • Patent number: 6833443
    Abstract: This invention relates to new Gymnemic acid derivatives, their preparation, pharmaceutical composition or extract which contains them, and their medical use, especially the use in the prevention or treatment of the diseases associated with hyperglycemia, hyperlipidemia and platelets aggregation.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: December 21, 2004
    Assignee: Guilin Jiqi Pharmaceutical Co., Ltd.
    Inventors: Wencai Ye, Yue Dai, Xiaodong Cong, Xingxiang Zhu, Shouxun Zhao
  • Patent number: 6833362
    Abstract: A composition for accelerating the disposal of ethanol from bodily fluid. Certain additives can accelerate the metabolic oxidation of ethanol, and others in addition act as catalysts or “pseudo” enzymes for the oxidation. Additives include the oxidant Nicotinamide Adenine Dinucleotide and a variety of other additives such as transition metal ions and complexes thereof which favor the oxidation reaction. The compositions described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: December 21, 2004
    Inventors: Ward Beryl Bowen, Jr., Daniel Salman Daniel
  • Publication number: 20040247703
    Abstract: Disclosed is a composition for inhibiting glutamate-mediated neurotoxicity comprising 20(S)-ginsenoside Rg3, 20(S)-ginsenoside Rh2 or the mixture of 20(S)-ginsenoside Rg3 and 20(S)-ginsenoside Rh2. The composition of the present invention has an excellent neurotoxicity inhibition effect or nerve cell protection effect. Accordingly, it can be effectively used for treating nervous diseases including cerebral trauma, cerebral apoplexy, cerebral hemorrhage; epilepsy occurred by excessive activation of glutamate receptors; or Huntington's disease.
    Type: Application
    Filed: October 27, 2003
    Publication date: December 9, 2004
    Inventors: Hyewhon Rhim, Sunoh Kim
  • Publication number: 20040247700
    Abstract: Compositions comprising an effective amount of a curcuminoid species and an effective amount of a diterpene lactone species, a triterpene species or derivatives thereof that have a synergistic effect on specific inhibition of inducible COX-2 activity and have minimal effect on COX-1 activity are disclosed. Methods of using the compositions for providing synergistic anti-inflammatory effects are also disclosed.
    Type: Application
    Filed: July 1, 2004
    Publication date: December 9, 2004
    Inventors: John G. Babish, Terrence Howell, Linda Pacioretty
  • Publication number: 20040242506
    Abstract: A salt formed from paroxetine hydrochloride and ammonium glycyrrhyzinate masks the bitter taste of paroxetine and has a distinctive liquorice flavour.
    Type: Application
    Filed: July 7, 2004
    Publication date: December 2, 2004
    Inventors: Nathalie Claude Marianne Barges Causeret, Nicola Lisa Anna Marzolini, Padma Meneaud
  • Publication number: 20040242502
    Abstract: The present invention discloses novel saponin derivatives for use with nucleic acids that induce an immune response when administered to animals and humans. The novel saponin derivatives disclosed comprise (a) a saponin aglycone core, wherein the aglycone core is covalently linked to one or more oligosaccharide chains; (b) a positively charged cationic chain, and optionally (c) a naturally occurring or synthetic lipophilic chain. Pharmaceutical and veterinary compositions comprising one or more of the novel saponin derivatives and saponin derivative/polynucleotide complexes are also disclosed. Disclosed as well are methods of using the novel saponin derivatives to deliver a polynucleotide molecule to cells of an animal, to stimulate or generate an immune response in an animal, and to generate a detectable immune response in an animal.
    Type: Application
    Filed: April 8, 2004
    Publication date: December 2, 2004
    Applicant: Galenica Pharmaceuticals, Inc.
    Inventor: Dante J. Marciani
  • Publication number: 20040241173
    Abstract: A fullerene-antibiotic conjugate including at least one antibiotic molecule per fullerene moiety. The fullerene may comprise C60 and the antibiotic may comprise vancomycin or may be selected from the group consisting of penicillins, cephalosporins, quinolones, fluoroquinolones, macrolides, lincosamines, carbepenems, conobactams, aminoglycosides, glycopeptides, tetracyclines, sulfonamides, rifampin, oxazolidonones, and streptogramins. The conjugate preferably includes at least two and more preferably at least three antibiotic molecules per C60 center. A method for making a fullerene(C60)-antibiotic conjugate, comprises: synthesizing a linker precursor (I); reacting the linker precursor (I) with C60 via a Bingel-reaction, to produce a fullerene-linker conjugate (II); hydrolyzing the fullerene-linker conjugate (II), resulting in a desired derivative of C60 (III); and reacting the derivative (III) with a desired antibiotic to produce a fullerene-antibiotic conjugate (IV).
    Type: Application
    Filed: February 11, 2004
    Publication date: December 2, 2004
    Applicant: William Marsh Rice University
    Inventors: Lon J. Wilson, Andrey L. Mirakyan, Matthew P. Cubbage
  • Publication number: 20040213808
    Abstract: An immunogenic composition is described which preferably contains recombinantly produced forms of truncated flavivirus envelope glycoproteins and an adjuvant. The disclosed immunogenic compositions can further comprise a recombinantly produced non-structural (non-envelope) flavivirus protein. The adjuvant typically comprises a saponin preferably derived from the Quillaja saponica tree or a derivative thereof. The adjuvant can also comprise an oligodeoxyribonucleotide preferably containing specific sequences of nucleotides described herein. A pharmaceutically acceptable vehicle may also be included in the immunogenic composition.
    Type: Application
    Filed: December 8, 2003
    Publication date: October 28, 2004
    Inventors: Michael Lieberman, Tom Humphreys
  • Publication number: 20040214783
    Abstract: Compositions and methods for treating a tumor, neoplastic disease or infectious disease in a subject are based on superantigens in the form of polypeptides including fusion polypeptides or conjugates, homologues, and fragments, all of which induce a tumoricidal response when administered directly into tumor or an organ sheath or body cavity affected by the tumor. Nucleic acid constructs encoding the foregoing polypeptides are also used in antitumor therapy. The above agents may be administered in sustained release or controlled release vehicles at or near sites of tumors in a tumor-bearing subject.
    Type: Application
    Filed: May 5, 2003
    Publication date: October 28, 2004
    Inventor: David S. Terman
  • Publication number: 20040202731
    Abstract: This invention is related to methods and compositions comprising rosmarinic acid. More specifically, the present invention comprises compositions comprising borneol, rosmarinic acid and at least one ginsenoside.
    Type: Application
    Filed: April 5, 2004
    Publication date: October 14, 2004
    Inventors: Robert T. Gow, Brian Pierce, John Pierce, William Birdsall
  • Publication number: 20040202730
    Abstract: This invention is related to an improved composition for treating heart conditions. More specifically, the present invention is related to an improved composition for treating heart conditions containing borneol, rosmarinic acid and a ginsenoside selected from the group consisting of ginsenoside Rg1 and ginsenoside Rb1.
    Type: Application
    Filed: April 8, 2003
    Publication date: October 14, 2004
    Inventors: Robert Gow, John Pierce, Brian Pierce, William Birdsall
  • Patent number: 6800615
    Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: October 5, 2004
    Assignees: Board of Trustees of Michigan State University, The Regent of the University of California, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow